Mayoly brings colchicine production back to France, securing domestic supply of an essential gout medication
Executive summary: Mayoly opened a colchicine manufacturing facility in Auxerre, France, on June 23, 2026. Domestic production ensures a stable supply of an essential gout medication for over 600,000 French patients and lessens dependence on imports.
Who is involved: Mayoly (French pharmaceutical lab), French healthcare system, patients requiring colchicine, and relevant regulatory authorities.
Likely next: The plant will ramp up output; stakeholders will monitor production volumes, pricing, and whether other firms follow similar reshoring initiatives.
The French laboratory Mayoly has inaugurated a new production line in Auxerre to manufacture colchicine, a drug prescribed to more than 600,000 patients in France and listed as a medicine of major therapeutic interest. This move reduces the country's reliance on foreign suppliers for a critical medication and aligns with broader efforts to strengthen pharmaceutical sovereignty. The inauguration highlights how reshoring can address supply‑chain vulnerabilities while supporting local manufacturing capacity.
Timeline
- — Le laboratoire Mayoly relocalise en France la production de colchicine, un médicament essentiel contre la goutte (Le Monde — Économie)
Analysis — what this means
Likely next events
- Other French pharma firms may evaluate reshoring of essential medicines.
Sectors affected
- Pharmaceuticals
- Healthcare
- Manufacturing
Regulatory implications
- Reinforcement of the essential medicines list compliance.
- Ongoing monitoring of drug pricing and supply security.
Historical parallels
- Reshoring of active pharmaceutical ingredients during the COVID‑19 pandemic.
- France’s earlier move to bring paracetamol production back domestically.
- EU strategic autonomy initiatives targeting medicine supply chains.
Key entities
Sources
Open the full interactive case file on Beyond →